Denali Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

DNLI$19.85-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Revenue:
Product revenue, net	$17,778	$—	$21,382	$—
Total revenue	17,778	—	21,382	—
Operating expenses:
Cost of goods sold	192	—	285	—
Research and development	106,102	101,950	306,967	320,873
Selling, general and administrative	37,485	35,484	107,279	97,104
Intangible asset amortization	750	—	1,500	—
Total operating expenses	144,529	137,434	416,031	417,977
Loss from operations	(126,751)	(137,434)	(394,649)	(417,977)
Other income:
Gain on sale of priority review voucher, net	194,000	—	194,000	—
Interest and other income, net	2,877	10,532	14,775	33,986
Total other income	196,877	10,532	208,775	33,986
Net income (loss)	$70,126	$(126,902)	$(185,874)	$(383,991)
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable securities, net of tax	(4,390)	162	(7,041)	(919)
Comprehensive income (loss)	$65,736	$(126,740)	$(192,915)	$(384,910)
Net income (loss) per share:
Basic	$0.37	$(0.74)	$(0.99)	$(2.24)
Diluted	$0.37	$(0.74)	$(0.99)	$(2.24)
Weighted-average shares used in calculating net income (loss) per share:
Basic	188,387,660	172,421,492	187,452,793	171,702,183
Diluted	192,077,855	172,421,492	187,452,793	171,702,183

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.